Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation
John Magenau(University of Michigan), Sung Won Choi(University of Michigan), Lyndsey Runaas(Medical College of Wisconsin), Mary Riwes(University of Michigan), Monalisa Ghosh(Michigan Medicine), Erin Gatza(Pediatrics and Genetics), Amanda Mazzoli(University of Michigan), Sarah Anand(University of Michigan), Grant Chappell(University of Michigan), Pavan Reddy(Wichita State University), Gregory A. Yanik(University of Michigan), Tracey Churay(University of Michigan), Joseph Brisson(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Thomas Braun(University of Michigan), Attaphol Pawarode(University of Michigan)
Cited by 6
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|420
A biomarker panel for acute graft-versus-host disease
|Blood|2008|404